Antiviral immunotherapy: emerging approaches with relevance to cutaneous disease

References

• Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol.560, 11–18 (2005).
   PubMed Web of Science ®Google Scholar
• Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res.16(2), 141–147 (2006).
   PubMed Web of Science ®Google Scholar
• Paladino P, Cummings DT, Noyce RS, Mossman KL. The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J. Immunol.177(11), 8008–8016 (2006).
   PubMed Web of Science ®Google Scholar
• Bowie AG. Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity. Clin Exp Immunol.147(2), 217–226 (2007).
   PubMed Web of Science ®Google Scholar
• Flacher V, Bouschbacher M, Verronese E et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol.177(11), 7959–7967 (2006).
   PubMed Web of Science ®Google Scholar
• Renn CN, Sanchez DJ, Ochoa MT et al. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J. Immunol.177(1), 298–305 (2006).
   PubMed Web of Science ®Google Scholar
• Pivarcsi A. Toll-like receptor 9-independent suppression of skin inflammation by oligonucleotides. J. Invest. Dermatol.127(4), 746–748 (2007).
   PubMed Web of Science ®Google Scholar
• Lebre MC, van der Aar AM, van Baarsen L et al. Human keratinocytes express functional Toll-like receptor 3,4,5 and 9. J. Invest. Dermatol.127(2), 331–341 (2007).
   PubMed Web of Science ®Google Scholar
• Galiana-Arnoux D, Imler JL. Toll-like receptors and innate antiviral immunity. Tissue Antigens67(4), 267–276 (2006).
   PubMedGoogle Scholar
• Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature248(450), 701–702 (1974).
   PubMed Web of Science ®Google Scholar
• Barton GM. Viral recognition by Toll-like receptors. Semin. Immunol.19(1), 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Bieback K, Lien E, Klagge IM et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol.76(17), 8729–8736 (2002).
   PubMed Web of Science ®Google Scholar
• Jude BA, Pobezinskaya Y, Bishop J et al. Subversion of the innate immune system by a retrovirus. Nat. Immunol.4(6), 573–578 (2003).
   PubMed Web of Science ®Google Scholar
• Hasan UA, Bates E, Takeshita F et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol.178(5), 3186–3197 (2007).
   PubMed Web of Science ®Google Scholar
• Harte MT, Haga IR, Maloney G et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med.197(3), 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• Balachandran S, Venkataraman T, Fisher PB, Barber GN. Fas-associated death domain-containing protein-mediated antiviral innate immune signaling involves the regulation of Irf7. J. Immunol.178(4), 2429–2439 (2007).
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity22(1), 59–70 (2005).
   PubMed Web of Science ®Google Scholar
• Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. Proc. Natl Acad. Sci. USA101(49), 17264–17269 (2004).
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA102(8), 2992–2997 (2005).
   PubMed Web of Science ®Google Scholar
• Foy E, Li K, Sumpter R Jr et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA102(8), 2986–2991 (2005).
   PubMed Web of Science ®Google Scholar
• Assier E, Marin-Esteban V, Haziot A, Maggi E, Charron D, Mooney N. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. J. Leukoc. Biol.81(1), 221–228 (2007).
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med.13(5), 552–559 (2007).
   PubMed Web of Science ®Google Scholar
• Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev. Med. Virol.17(1), 35–43 (2007).
   PubMed Web of Science ®Google Scholar
• Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J.25(18), 4207–4214 (2006).
   PubMed Web of Science ®Google Scholar
• Alter G, Suscovich TJ, Teigen N et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J. Immunol.178(12), 7658–7666 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β. Blood109(2), 619–625 (2007).
   PubMed Web of Science ®Google Scholar
• Stack J, Haga IR, Schroder M et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med.201(6), 1007–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Lenz P, Lowy DR, Schiller JT. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur. J. Immunol.35(5), 1548–1556 (2005).
   PubMed Web of Science ®Google Scholar
• Carter WA, Ventura D, Shapiro DE, Strayer DR, Gillespie DH, Hubbell HR. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease. Int. J. Immunopharmacol.13(Suppl. 1), 69–76 (1991).
   PubMed Web of Science ®Google Scholar
• Padalko E, Nuyens D, De Palma A et al. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob. Agents Chemother.48(1), 267–274 (2004).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol.178(8), 5200–5208 (2007).
   PubMed Web of Science ®Google Scholar
• Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis.190(10), 1841–1849 (2004).
   PubMed Web of Science ®Google Scholar
• Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature433(7028), 887–892 (2005).
   PubMed Web of Science ®Google Scholar
• Wang JP, Asher DR, Chan M, Kurt-Jones EA, Finberg RW. Cutting Edge: Antibody-mediated TLR7-dependent recognition of viral RNA. J. Immunol.178(6), 3363–3367 (2007).
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol.174(3), 1259–1268 (2005).
   PubMed Web of Science ®Google Scholar
• Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr. Med. Chem.14(6), 681–687 (2007).
   PubMed Web of Science ®Google Scholar
• Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J.21(7), 1575–1585 (2007).
   PubMed Web of Science ®Google Scholar
• Camateros P, Tamaoka M, Hassan M et al. Chronic asthma induced airway remodeling is prevented by the Toll-like receptor 7/8 ligand S28463. Am. J. Respir. Crit. Care Med.175(12), 1241–1249 (2007).
   PubMed Web of Science ®Google Scholar
• Vidal D. Topical imiquimod: mechanism of action and clinical applications. Mini Rev. Med. Chem.6(5), 499–503 (2006).
   PubMed Web of Science ®Google Scholar
• Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis74(2), 134–142 (2004).
   PubMed Web of Science ®Google Scholar
• Schacker TW, Conant M, Thoming C, Stanczak T, Wang Z, Smith M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a Phase II, randomized, double-blind, placebo-controlled study. Antimicrob. Agents Chemother.46(10), 3243–3248 (2002).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis.184(2), 196–200 (2001).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov.5(6), 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Kerkmann M, Lochmann D, Weyermann J et al. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides16(4), 313–322 (2006).
   PubMedGoogle Scholar
• De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol.30(2), 115–133 (2004).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Martin RR. Was induction of HIV-1 through TLR9? J. Immunol.171(4), 1621 (2003).
   PubMed Web of Science ®Google Scholar
• Schlaepfer E, Audige A, von Beust B et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J. Virol.78(22), 12344–12354 (2004).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Cartier JL, Patrick AJ et al. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res.69(2), 77–85 (2006).
   PubMed Web of Science ®Google Scholar
• Dorn A, Ludwig RJ, Bock A et al. Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J. Invest. Dermatol.127(4), 846–854 (2007).
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Ahmad-Nejad P, da Costa C et al. Endocytosed Hsp60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem.276(33), 31332–31339 (2001).
   PubMed Web of Science ®Google Scholar
• Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (Hsp) 60 activates the innate immune response: CD14 is an essential receptor for Hsp60 activation of mononuclear cells. J. Immunol.164(1), 13–17 (2001).
   Web of Science ®Google Scholar
• Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J. Cell Biol.158(7), 1277–1285 (2002).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat. Immunol.1(2), 151–155 (2000).
   PubMed Web of Science ®Google Scholar
• Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity17(3), 353–362 (2002).
   PubMed Web of Science ®Google Scholar
• Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl Acad. Sci. USA91(8), 3077–3081 (1994).
   PubMed Web of Science ®Google Scholar
• Heikema A, Agsteribbe E, Wilschut J, Huckriede A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett.57(1–3) 69–74 (1997).
   PubMed Web of Science ®Google Scholar
• Zugel U, Sponaas AM, Neckermann J, Schoel B, Kaufmann SH. gp96-peptide vaccination of mice against intracellular bacteria. Infect. Immun.69(6), 4164–4167 (2001).
   PubMed Web of Science ®Google Scholar
• Suzue K, Young RA. Heat shock proteins as immunological carriers and vaccines. EXS77, 451–465 (1996).
   PubMedGoogle Scholar
• Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines2(3), 369–379 (2003).
   PubMedGoogle Scholar
• Palefsky JM, Berry JM, Jay N et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS20(8), 1151–1155 (2006).
   PubMed Web of Science ®Google Scholar
• von Nida J, Quirk C. Successful treatment of in-transit melanoma metastases using topical 2–4 dinitrochlorobenzene. Australas. J. Dermatol.44(4), 277–280 (2003).
   PubMedGoogle Scholar
• Liu SJ, Tsai JP, Shen CR et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-{β} and interleukin-6. J. Leukoc. Biol. (2007) (Epub ahead of print).
   Google Scholar
• He D, Wu L, Kim HK, Li H, Elmets CA, Xu H. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J. Immunol.177(10), 6852–6858 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Andoh A, Inatomi O et al. Interleukin-17 and lipopolysaccharides synergistically induce cyclooxygenase-2 expression in human intestinal myofibroblasts. J. Gastroenterol. Hepatol.20(4), 619–627 (2005).
   PubMed Web of Science ®Google Scholar
• Smiley KL, McNeal MM, Basu M, Choi AH, Clements JD, Ward RL. Association of γ interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). J. Virol.81(8), 3740–3748 (2007).
   PubMed Web of Science ®Google Scholar
• Pestka J, Zhou HR. Toll-like receptor priming sensitizes macrophages to proinflammatory cytokine gene induction by deoxynivalenol and other toxicants. Toxicol. Sci.92(2), 445–455 (2006).
   PubMed Web of Science ®Google Scholar
• Aiba S, Katz SI. Phenotypic and functional characteristics of in vivo-activated Langerhans cells. J. Immunol.145(9), 2791–2796 (1990).
   PubMed Web of Science ®Google Scholar
• Iijima N, Yanagawa Y, Onoe K. Role of early- or late-phase activation of p38 mitogen-activated protein kinase induced by tumour necrosis factor-α or 2,4-dinitrochlorobenzene during maturation of murine dendritic cells. Immunology110(3), 322–328 (2003).
   PubMed Web of Science ®Google Scholar
• Boisleve F, Kerdine-Romer S, Rougier-Larzat N, Pallardy M. Nickel and DNCB induce CCR7 expression on human dendritic cells through different signalling pathways: role of TNF-α and MAPK. J. Invest. Dermatol.123(3), 494–502 (2004).
   PubMed Web of Science ®Google Scholar
• Ebner S, Lenz A, Reider D, Fritsch P, Schuler G, Romani N. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiology198(5) 568–587 (1998).
   PubMed Web of Science ®Google Scholar
• Staquet MJ, Sportouch M, Jacquet C, Schmitt D, Guesnet J, Peguet-Navarro J. Moderate skin sensitizers can induce phenotypic changes on in vitro generated dendritic cells. Toxicol. In Vitro.18(4), 493–500 (2004).
   PubMed Web of Science ®Google Scholar
• Schwarzenberger K, Udey MC. Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J. Invest. Dermatol.106(3), 553–558 (1996).
   PubMed Web of Science ®Google Scholar
• Weiss JM, Sleeman J, Renkl AC et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J. Cell Biol.137(5), 1137–1147 (1997).
   PubMed Web of Science ®Google Scholar
• Aiba S, Nakagawa S, Ozawa H, Miyake K, Yagita H, Tagami H. Up-regulation of α 4 integrin on activated Langerhans cells: analysis of adhesion molecules on Langerhans cells relating to their migration from skin to draining lymph nodes. J. Invest. Dermatol.100(2), 143–147 (1993).
   PubMed Web of Science ®Google Scholar
• Kobayashi Y. Langerhans’ cells produce type IV collagenase (MMP-9) following epicutaneous stimulation with haptens. Immunology90(4), 496–501 (1997).
   PubMed Web of Science ®Google Scholar
• Martin SF. T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int. Arch. Allergy Immunol.134(3), 186–198 (2004).
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol.21(12), 2415–2432 (2003).
   PubMed Web of Science ®Google Scholar
• O’Neill D, Bhardwaj N. Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol. Med.109, 97–112 (2005).
   PubMedGoogle Scholar
• Lewis HM. Topical immunotherapy of refractory warts. Cutis12, 863–867 (1973).
   Google Scholar
• Upitis JA, Krol A. The use of diphenylcyclopropenone in the treatment of recalcitrant warts. J. Cutan. Med. Surg.6(3), 214–217 (2002).
   PubMed Web of Science ®Google Scholar
• Orecchia G, Douville H, Santagostino L, Rabbiosi G. Treatment of multiple relapsing warts with diphenciprone. Dermatologica177(4), 225–231 (1988).
   PubMedGoogle Scholar
• Puig L, Alegre M, Cuatrecasas M, De Moragas JM. Erythema multiforme-like reaction following diphencyprone treatment of plane warts. Int. J. Dermatol.33(3), 201–203 (1994).
   PubMed Web of Science ®Google Scholar
• Johansson E, Forstrom L. Dinitrochlorbenzene (DNCB) treatment of viral warts. A 5-year follow-up study. Acta Derm. Venereol.64(6), 529–533 (1984).
   PubMed Web of Science ®Google Scholar
• Petrelli R, Cotlier E, Robins S, Stoessel K. Dinitrochlorobenzene immunotherapy of recurrent squamous papilloma of the conjunctiva. Ophthalmology88(12), 1221–1225 (1981).
   PubMed Web of Science ®Google Scholar
• Dall’Oglio F, Nasca MR, D’Agata O, Micali G. Adult and paediatric contact immunotherapy with squaric acid dibutylester (SADBE) for recurrent, multiple, resistant, mucocutaneous anogenital warts. Sex Transm. Infect.78(4), 309–310 (2002).
   Google Scholar
• Naylor MF, Neldner KH, Yarbrough GK, Rosio TJ, Iriondo M, Yeary J. Contact immunotherapy of resistant warts. J. Am. Acad. Dermatol.19(4), 679–683 (1988).
   PubMed Web of Science ®Google Scholar
• Rampen FH, Steijlen PM. Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Dermatology193(3), 236–238 (1996).
   PubMed Web of Science ®Google Scholar
• Micali G, Dall’Oglio F, Tedeschi A, Pulvirenti N, Nasca MR. Treatment of cutaneous warts with squaric acid dibutylester: a decade of experience. Arch. Dermatol.136(4), 557–558 (2000).
   PubMedGoogle Scholar
• Weisshaar E, Neumann HJ, Gollnick H. Successful treatment of disseminated facial verrucae with contact immunotherapy. Eur. J. Dermatol.8(7), 488–491 (1998).
   PubMed Web of Science ®Google Scholar
• Pollock B, Highet AS. An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts. J. Dermatolog. Treat.13(2), 47–50 (2002).
   PubMed Web of Science ®Google Scholar
• Georgala S, Danopoulou I, Katsarou A. Dinitrochlorobenzene treatment of condylomata acuminata. Australas. J. Dermatol.30(2), 103–105 (1989).
   PubMedGoogle Scholar
• Guthrie D, Way S. Immunotherapy of non-clinical vaginal cancer. Lancet2(7947), 1242–1243 (1975).
   PubMed Web of Science ®Google Scholar
• Levis WR, Holzer AM, Leonard LK. Topical diphenylcyclopropenone as a measure of immune competence in HIV-seropositive subjects. J. Drugs Dermatol.5(9), 853–858 (2006).
   PubMedGoogle Scholar
• Callard RE. Decision-making by the immune response. Immunol. Cell. Biol.85(4), 300–305 (2007).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol.4(4), 330–336 (2003).
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol.25, 221–242 (2007).
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol.25, 821–852 (2007).
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell126(6), 1121–1133 (2006).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature441(7090), 235–238 (2006).
   PubMed Web of Science ®Google Scholar
• Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity24(6), 677–688 (2006).
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol.8(4), 369–377 (2007).
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity24(2), 179–189 (2006).
   PubMed Web of Science ®Google Scholar
• Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med.194(4), 519–527 (2001).
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature441(7090), 231–234 (2006).
   PubMed Web of Science ®Google Scholar
• Leibundgut-Landmann S, Gross O, Robinson MJ et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol.8(6), 630–638 (2007).
   PubMed Web of Science ®Google Scholar
• Maek-A-Nantawat W, Buranapraditkun S, Klaewsongkram J, Ruxrungthum K. Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol.20(1), 66–75 (2007).
   PubMed Web of Science ®Google Scholar